XIAP and acute myeloid leukemia: Phase I/II trial results for XIAP ASOs both as a single agent and in combination with chemotherapy in refractory/relapsed AML have recently been published using a variety of dosing schedules (AEG35156, Aegera Therapeutics Inc. Montreal, Québec, Canada) (Dean et al, 2009; Schimmer et al, 2009).